

Ad hoc announcement pursuant to Art. 53 LR

April 24, 2026

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2026, which covers the results of its business activities for the first three months of 2026.

Based on the consolidated accounts of BB Biotech AG, net loss for the period ended March 31, 2026, amounted to CHF 21 mn (loss of CHF 241 mn in the same period 2025). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2026, is available under www.bbbiotech.com.

For further information:

Bellevue Asset Management AG, Theaterstrasse 12, 8001 Zurich, Switzerland, tel. +41 44 267 67 00

Head BB Biotech Team

Dr. Christian Koch

Head Investor Relations

ir@bbbiotech.com

Rachael Burri, rbu@bellevue.ch

Media Relations

Tanja Chicherio, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech AG is an investment company with its registered office in Schaffhausen/Switzerland and listed on the Swiss and German stock exchanges. It has invested in innovative drug developers headquartered primarily in the US and Western Europe. BB Biotech is one of the world's largest investors in this sector. The competent Board of Directors with its long-standing experience set the investment strategy and guidelines. Investment decisions are taken by the experienced investment management team of Bellevue Asset Management AG based on their extensive investment research.